Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in previously treated HER2-positive metastatic breast cancer
2015-000380-13Phase 3Completed
- Sponsor
- MacroGenics
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Margetuximab plus chemotherapy with Trastuzumab plus chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2015; status: completed.
02
Drugs
margetuximabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-000380-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000380-13.